Clinical Trial Update: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 3]

View source ↗

Summary

This update reports the Phase 3 results of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Failure
• Dopamine Beta-hydroxylase Deficiency
• Neurogenic Orthostatic Hypotension
• Non-diabetic Neuropathy

Drugs mentioned

• Droxidopa (Northera) (droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2014-05-20